GeneDx Faces Securities Lawsuit Following Fabric Genomics Write-off

The legal action, spearheaded by Hagens Berman, targets the period between April 16, 2025, and May 4, 2026. Plaintiffs claim the company provided false assurances about the durability of its average reimbursement rate and the growth potential of its diagnostic business model. While management had projected consistent growth and steady margins earlier in the year, the company’s Q1 2026 earnings report revealed a drastic shift in performance.

On May 4, 2026, GeneDx disclosed a massive increase in net losses, largely driven by a $31.2 million impairment charge related to Fabric Genomics—effectively writing off 94% of the unit's acquisition cost just one year after purchase. The company also reported that its average reimbursement rate fell $200 short of previous guidance, attributing the shortfall to an unexpected shift in product mix. Consequently, GeneDx slashed its 2026 revenue forecast by 12%, prompting the current investigation into whether management intentionally obscured the unit's true value and the underlying instability of its clinical diagnostic operations.